Page 169 - Drug Class Review

Drug Effectiveness Review Project
Alzheimer classification: Mild-moderate
Groups similar at baseline: Yes

Health Outcome Measures: 0.929)

Authors and Year: Rockwood et al. 2001; Markowitz et al. 2003
galantamine placebo 74.6 75.2 53.6 56.7 NR NR 89.6% 90.0% 19.7 19.6 Primary Outcome Measures: ADAS-Cog 11; CIBIC-plus Secondary Outcome Measures: ADAS-Cog 13; ADAS-Cog 11 responders (≥ 4 point improvement); NPI; DAD; PSQI; NPI sleep score Timing of assessments: Baseline and months 1 and 3 Activities of daily living were significantly better in GAL group than in placebo group (DAD score: +4.3 points; P = 0.004) No significant differences in sleep quality between groups (PSQI: P = 0.929; NPI sleep score: P = No significant differences in behavioral

• • • • • •

Final Report Update 1 POPULATION CHARACTERISTICS: Mean age (years): Sex (% female): Ethnicity: Other germane population qualities: Other medical conditions • MMSE score • OUTCOME ASSESSMENT: RESULTS: Alzheimer's Drugs